Category: Pharmaceuticals
Pharmaceuticals market research reports by DelveInsight
-
TGF-Beta-1 Inhibitor - Pipeline Insight, 2025
DelveInsight’s, “TGF-Beta-1 Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in TGF-Beta-1 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the the ... Read More
-
Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2025
“Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Transient Receptor Pot ... Read More
-
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025
DelveInsight’s, “Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Glucagon-Like Peptide 1 Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclin ... Read More
-
Potassium channel antagonists - Pipeline Insight, 2025
DelveInsight’s, “Potassium channel antagonists - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Potassium channel antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
-
Complement C1 inhibitors - Pipeline Insight, 2025
DelveInsight’s, “Complement C1 Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complement C1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More
-
Gaucher's Disease Type III - Pipeline Insight, 2025
DelveInsight’s, “Gaucher’s disease type III - Pipeline Insight, 2025,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Gaucher’s disease type III pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also co ... Read More
-
Gaucher’s Disease Type I - Pipeline Insight, 2025
DelveInsight’s, “Gaucher’s Disease Type I - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Gaucher’s Disease Type I pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More
-
Allergic Rhinitis - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the Allergic Rhinitis Market Size was highest in the US among the 7MM, accounting for approximately USD 3,600 million which is further expected to increase by 2034. In 2023, the prevalence of Allergic rhinitis was highest in Japan among the 7MM, accounting for approximately 6 ... Read More
-
Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights: Irritable bowel syndrome is believed to be a multifactorial disease involving motility dysfunction, visceral hypersensitivity, psychiatric comorbidity, neuroendocrine dysfunction, genetics and epigenetics, diet, and immune activation. Approximately 32 million cases of irritable bowel ... Read More
-
WHIM Syndrome - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights WHIM syndrome is a rare genetic disorder caused by CXCR4 mutations, leading to immunodeficiency, warts, hypogammaglobulinemia, and myelokathexis. In 2023, the diagnosed prevalent population in the 7MM was estimated to be around 179 individuals. WHIM is a significant health issue in th ... Read More
-
Post-Bariatric Hypoglycemia - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the United States accounted for approximately 90% of the total Post-Bariatric hypoglycemia market size within the seven major markets. Post-Bariatric hypoglycemia is the development of hypoglycemia (low blood sugar) following bariatric surgery, such as gastric bypass or sleev ... Read More
-
1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025
“1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 1,3-Beta-Glucan Synthase Inhibitor development. The report provides detailed coverage of the pipeli ... Read More
-
5-HT4 Agonist - Pipeline Insight, 2025
“5-HT4 Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT4 Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, ... Read More
-
Adenosine A1 Receptor Agonist - Pipeline Insight, 2025
“Adenosine A1 Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A1 Receptor Agonist development. The report provides detailed coverage of the pipeline landsca ... Read More
-
Adenosine A3 Receptor Antagonist - Pipeline Insight, 2025
“Adenosine A3 Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A3 Receptor Antagonist development. The report provides detailed coverage of the pipeline l ... Read More
-
Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025
“Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A2A Receptor Antagonist development. The report provides detailed coverage of the pipeline ... Read More
-
Alpha Receptor Antagonist - Pipeline Insight, 2025
“Alpha Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for t ... Read More
-
Alpha-2 Antagonist - Pipeline Insight, 2025
“Alpha-2 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha-2 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism ... Read More
-
Amyloid Protein Blockers - Pipeline Insight, 2025
“Amyloid Protein Blockers - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Amyloid Protein Blockers development. The report provides detailed coverage of the pipeline landscape for thi ... Read More
-
Angiopoietin Inhibitor - Pipeline Insight, 2025
“Angiopoietin Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiopoietin Inhibitor development. The report provides detailed coverage of the pipeline landscape for this me ... Read More
-
Factor IX - Pipeline Insight, 2025
DelveInsight’s, “Factor IX - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Factor IX pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by ... Read More
-
Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2025
“Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-13 (IL-13) Inhibitor development. The report provides detailed coverage of the pipeline l ... Read More
-
Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2025
“Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-12 (IL-12) Inhibitor development. The report provides detailed coverage of the pipeline l ... Read More
-
Gaucher's disease - Pipeline Insight, 2025
DelveInsight’s, “Gaucher’s Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 14+ companies and 16+ pipeline drugs in Gaucher’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therape ... Read More
-
Gaucher disease Type 1 - Pipeline Insight, 2025
DelveInsight’s, “Gaucher disease Type 1 - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gaucher disease Type 1 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ... Read More
Research Assistance
